# V1 Empirics Check — openai/gpt-5.4 (Variant B)

**Model:** openai/gpt-5.4
**Variant:** B
**Date:** 2026-03-22T14:04:13.306897

---

## 1. Idea Fidelity

The paper pursues the broad spirit of the manifest: it studies whether coroner versus medical examiner (ME) systems affect the measurement of opioid/drug overdose mortality, using CDC COMEC county MDI classifications and a within-state border-county comparison. It also retains the central policy motivation that institutional differences in death investigation may bias downstream empirical work on the opioid epidemic.

That said, it departs from the original idea in several important ways, and mostly in directions that weaken the contribution. Most importantly, the manifest’s key outcome was **classification quality**—especially the share of overdose deaths coded as unspecified versus drug-specific using CDC WONDER/VSRR data. The paper instead uses **NCHS model-based county overdose death rates** as its primary outcome. This is a major conceptual shift: lower recorded overdose mortality in coroner counties is only an indirect proxy for misclassification, and it is much harder to distinguish from real differences in underlying overdose risk. The paper also drops several elements that were central to the original identification and interpretation strategy: there is no direct use of unspecified-drug codes, no mechanism evidence on autopsies or toxicology, and no falsification outcomes such as cancer or heart disease mortality. Finally, the manifest emphasized 16 mixed states and 500+ border pairs; the paper uses 13 states and 331 pairs without much discussion of why the feasible sample is smaller.

## 2. Summary

This paper argues that counties with elected coroners undercount drug overdose deaths relative to otherwise similar counties with appointed medical examiners. Using county-level MDI classifications and adjacent within-state county comparisons, it finds lower measured overdose mortality in coroner counties and interprets this as evidence of a substantial “detection gap” in U.S. mortality statistics.

The question is important, and the paper is clearly written. But in its current form, the evidence does not convincingly isolate mismeasurement from genuine differences in overdose mortality, so the causal and quantitative claims are substantially stronger than the design can support.

## 3. Essential Points

1. **The outcome does not match the causal claim.**  
   The paper’s central claim is about misclassification and undercounting, but the outcome is total county overdose mortality from NCHS model-based estimates, not a direct measure of classification quality. A lower overdose rate in coroner counties could reflect worse death certification, but it could also reflect lower true overdose mortality. This is the paper’s fundamental identification problem. To make a credible contribution, the analysis needs to return to the original outcome concept: unspecified-drug coding shares, drug-specific coding, or other direct indicators of certification quality. Without that, the paper should be framed much more cautiously as documenting a correlation between MDI structure and measured mortality, not a causal “detection gap.”

2. **The border-pair design is not sufficient for causal identification as implemented.**  
   MDI type is time-invariant, and the panel largely repeats the same cross-sectional treatment contrast over time. Border-pair comparisons help, but they do not eliminate county-level unobservables that may be correlated with both MDI structure and true overdose risk—urbanicity, hospital systems, illicit drug supply routes, policing, labor markets, and health care access, among others. The paper repeatedly states or implies quasi-random assignment, which is not justified. At minimum, the authors need a much more modest interpretation and much stronger validation: balance tests within pairs, geographic trend controls, placebo outcomes, and evidence that pre-fentanyl differences were small or absent if the story is really about forensic complexity.

3. **The use of NCHS model-based estimates is problematic for a paper about measurement error.**  
   These estimates are constructed precisely to smooth sparse county outcomes by borrowing strength across places and time. That may be useful for descriptive public health work, but it is awkward here because the paper’s object of interest is institutionally driven local measurement error. The model-based outcome may attenuate, distort, or even partly impute away the very variation the paper seeks to study. The paper needs to justify this choice carefully and show that results are not an artifact of the modeling procedure—ideally by using raw mortality/count data where feasible, even if only for larger counties or aggregated periods.

## 4. Suggestions

The paper tackles an important issue, and there is a potentially publishable paper here if the design is tightened and the claims are better aligned with the evidence. My suggestions below are aimed at helping the authors recover the strongest version of the project.

**First, re-center the paper around direct evidence on classification quality.**  
The current version infers misclassification from lower total overdose mortality, but the paper would be much stronger if it directly examined whether coroner counties are more likely to classify overdose deaths as unspecified or less likely to identify opioids/synthetic opioids specifically. That was the most compelling feature of the original idea. Even if county-level public-use data are imperfect, there are several ways forward:
- Use county-year or county-period measures of unspecified drug poisoning where available.
- Aggregate smaller counties into multi-year bins to reduce suppression.
- Restrict to larger counties for a cleaner validation exercise.
- Use state or substate tabulations as a complementary validation even if the preferred design remains county-level.
A paper that shows “coroner counties have more unspecified overdose coding” is much closer to the claimed mechanism than one that shows “coroner counties have lower overdose rates.”

**Second, add falsification outcomes aggressively.**  
The manifest rightly proposed causes of death not dependent on forensic toxicology, such as cancer or heart disease. These placebo outcomes are essential. If coroner counties also have systematically lower cancer mortality in the same border-pair design, that would suggest broader differences in health environments or data construction rather than overdose-specific undercounting. Conversely, a null on causes less dependent on death investigation would substantially strengthen your argument. I would also encourage placebo outcomes within external causes that should be less sensitive to toxicology, if available.

**Third, show the institutional mechanism more directly.**  
Right now the mechanism is asserted rather than demonstrated. The paper would benefit greatly from evidence on:
- autopsy rates,
- toxicology testing capacity,
- office staffing/resources,
- whether effects are larger in places more likely to rely on limited forensic infrastructure,
- whether the gap is larger for synthetic opioids than for broader drug categories.
Even descriptive mechanism evidence would help. If COMEC or related BJS sources contain county- or office-level information on autopsy shares, budgets, or staffing, interact those measures with MDI type. A finding that the gap is concentrated where coroners perform fewer autopsies would be much more convincing.

**Fourth, be more careful about the interpretation of the border design.**  
Adjacent counties are better comparisons than arbitrary counties, but they are not automatically comparable. I recommend:
- presenting a map of the border-pair sample,
- showing balance tables within mixed-state border pairs,
- estimating specifications with pair fixed effects plus flexible controls for population density, urbanicity, hospital capacity, and baseline mortality,
- checking robustness to dropping major metro counties or, separately, only using metro-adjacent pairs,
- weighting pairs symmetrically so a few large states or clustered counties do not dominate.
The design should be presented as reducing confounding, not delivering near-random assignment.

**Fifth, address the time dimension more convincingly.**  
The widening gap is intuitive, but as shown it is not very probative: many other county differences also evolved over 2003–2021. A more persuasive approach would be an event-style or difference-in-differences framework tied to the rise of synthetic opioids. For example, compare whether coroner-ME differences expand disproportionately after 2013/2014, when fentanyl becomes much more important, especially in places more exposed to fentanyl. This would align the timing with the proposed mechanism rather than simply documenting a trend.

**Sixth, justify and stress-test the NCHS model-based outcome.**  
If the authors continue to use these estimates, they need to explain exactly what information enters the model and whether certification differences in raw data survive the smoothing procedure. At minimum, show:
- robustness in larger counties using unsuppressed raw CDC WONDER counts/rates,
- robustness when aggregating to 3-year or 5-year periods,
- sensitivity to excluding very small counties where model-based imputation matters most.
A measurement-error paper should be especially transparent about relying on modeled outcomes.

**Seventh, reconsider the national undercount calculation.**  
At present this extrapolation is too strong given the identification challenges and the local nature of the border estimate. Border counties in mixed states may not represent all coroner counties, especially those in uniformly coroner states. Also, translating a reduced-form difference in measured overdose mortality into a national count of “undetected deaths” assumes away all residual confounding. I would either drop this calculation or move it to a clearly labeled back-of-the-envelope exercise with wide uncertainty bounds and much more caveat language.

**Eighth, the paper should distinguish between drug-overdose undercounting and opioid-specific undercounting.**  
The title and framing emphasize the opioid epidemic, but the empirical outcome is overall drug poisoning mortality. That is not necessarily a problem, but the current framing overshoots the evidence. If opioid-specific coding cannot be observed in the chosen data, then the paper should be reframed around drug overdose mortality more broadly, with discussion of opioids as a likely but unverified component.

**Ninth, improve transparency around sample construction.**  
The paper should explain:
- why only 13 mixed states appear, not 16 as the underlying idea suggested,
- why only 297 unique counties appear in 331 pairs,
- how counties entering multiple pairs are handled,
- whether standard errors account for this non-independence,
- whether the estimates change when selecting one nearest neighbor pair per county or collapsing to pair averages.
These details matter for inference and interpretation.

**Tenth, moderate the rhetoric.**  
Statements such as “no one had died fewer times,” “the same overdose victim… can be classified as… cause unknown,” and “enough to alter the trajectory of every county-level opioid regression” are too strong relative to the evidence presented. AER: Insights papers can be punchy, but the argument must be tighter than it currently is. The paper will be more credible if it states that the evidence is consistent with substantial institutional measurement differences, rather than claiming to have cleanly identified the causal magnitude of undercounting.

Overall, this is a promising and policy-relevant topic. But the paper’s current empirical design supports a strong descriptive finding—coroner counties have lower measured overdose mortality than nearby ME counties—more than the stronger causal conclusion that coroner systems generate a specific, quantified undercount of overdose deaths. Tightening the outcome measure, adding validation and falsification tests, and toning down the extrapolation would substantially improve the paper.
